Roque DM, Siegel ER, Buza N, Bellone S, et al. Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Br J Cancer 2022 Feb 11. pii: 10.1038/s41416-022-01717.
PMID: 35149854